Does the world need an Omicron vaccine? What researchers say

The US Centers for Disease Control and Prevention (CDC) on 21January similarly said that a third shot prevented visits to the emergency room or urgent care with 82% effectiveness, and hospitalization with 90% effectiveness, for people infected with Omicron (M. G. Thompson et al. Essential to those d...

Full description

Saved in:
Bibliographic Details
Published inNature (London) Vol. 602; no. 7896; pp. 192 - 193
Main Author Waltz, Emily
Format Journal Article
LanguageEnglish
Published England Nature Publishing Group 10.02.2022
Subjects
Allergies
Coronaviruses
COVID-19
COVID-19 vaccines
Disease control
Disease transmission
Emergency medical care
Emergency medical services
Epidemics
Hospitalization
Humans
Infectious diseases
Influenza
Medical research
SARS-CoV-2
Science and technology
Severe acute respiratory syndrome coronavirus 2
Technology policy
Vaccines
Viral diseases
United Kingdom > UK
United States > US
SARS-CoV-2
Public health
Vaccines
Online AccessGet full text

Cover

More Information
Summary:The US Centers for Disease Control and Prevention (CDC) on 21January similarly said that a third shot prevented visits to the emergency room or urgent care with 82% effectiveness, and hospitalization with 90% effectiveness, for people infected with Omicron (M. G. Thompson et al. Essential to those discussions are data on the duration of protection that a third dose provides, says Matthew Hepburn, a senior adviser at the White House Office of Science and Technology Policy. The US National Institute of Allergy and Infectious Diseases (NIAID) and the global Coalition for Epidemic Preparedness Innovations (CEPI), as well as other institutes, have been funding research to develop a pan-coronavirus vaccine that broadly protects against many strains of SARS-CoV-2 and other types of coronavirus.
Bibliography:SourceType-Other Sources-1
ObjectType-News-1
ObjectType-Commentary-2
content type line 66
ISSN:0028-0836
1476-4687
DOI:10.1038/d41586-022-00199-z